A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany

被引：0
|
作者：
Maureen Watt
Charles McCrea
Sukhvinder Johal
John Posnett
Jameel Nazir
机构：
[1] Astellas EMEA,
[2] PAREXEL Access Consulting,undefined
[3] Astellas Pharma Europe Ltd.,undefined
来源：
Infection | 2016年 / 44卷
关键词：
Cost-effectiveness; Budget impact; Fidaxomicin; Vancomycin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：599 / 606
页数：7
相关论文
共 50 条
  • [21] Cost-effectiveness of Fecal Microbiota Transplantation for First Recurrent Clostridioides difficile Infection
    Aby, Elizabeth S.
    Vaughn, Byron P.
    Enns, Eva A.
    Rajasingham, Radha
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (09) : 1602 - 1609
  • [22] Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review
    Al Momani, Laith A.
    Abughanimeh, Omar
    Boonpheng, Boonphiphop
    Gabriel, Joseph Gabriel
    Young, Mark
    CUREUS, 2018, 10 (06):
  • [23] Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain
    C. Rubio-Terrés
    J. Cobo Reinoso
    S. Grau Cerrato
    J. Mensa Pueyo
    M. Salavert Lletí
    A. Toledo
    P. Anguita
    D. Rubio-Rodríguez
    M. Watt
    R. Gani
    European Journal of Clinical Microbiology & Infectious Diseases, 2015, 34 : 2213 - 2223
  • [24] Cost-effectiveness analysis of ribotype-guided fecal microbiota transplantation in Chinese patients with severe Clostridium difficile infection
    Jiang, Minghuan
    Leung, Nok-Hang
    Ip, Margaret
    You, Joyce H. S.
    PLOS ONE, 2018, 13 (07):
  • [25] The cost-effectiveness and budgetary impact of a dolutegravir-based regimen as first-line treatment of HIV infection in India
    Zheng, Amy
    Kumarasamy, Nagalingeswaran
    Huang, Mingshu
    Paltiel, A. David
    Mayer, Kenneth H.
    Rewari, Bharat B.
    Walensky, Rochelle P.
    Freedberg, Kenneth A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21 (03)
  • [26] Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain
    Rubio-Terres, C.
    Cobo Reinoso, J.
    Grau Cerrato, S.
    Mensa Pueyo, J.
    Salavert Lleti, M.
    Toledo, A.
    Anguita, P.
    Rubio-Rodriguez, D.
    Watt, M.
    Gani, R.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2015, 34 (11) : 2213 - 2223
  • [27] Cost-effectiveness of three different strategies for the treatment of first recurrent Clostridium difficile infection diagnosed in a community setting
    Lam, Simon W.
    Neuner, Elizabeth A.
    Fraser, Thomas G.
    Delgado, David
    Chalfin, Donald B.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2018, 39 (08) : 924 - 930
  • [28] Cost-Effectiveness Analysis of Probiotic Use to Prevent Clostridium difficile Infection in Hospitalized Adults Receiving Antibiotics
    Shen, Nicole T.
    Leff, Jared A.
    Schneider, Yecheskel
    Crawford, Carl V.
    Maw, Anna
    Bosworth, Brian
    Simon, Matthew S.
    OPEN FORUM INFECTIOUS DISEASES, 2017, 4 (03):
  • [29] Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors
    Cortesi, Paolo Angelo
    Castaman, Giancarlo
    Trifiro, Gianluca
    Creazzola, Simona Serao
    Improta, Giovanni
    Mazzaglia, Giampiero
    Molinari, Angelo Claudio
    Mantovani, Lorenzo Giovanni
    THROMBOSIS AND HAEMOSTASIS, 2020, 120 (02) : 216 - 228
  • [30] Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China
    Zhao, Jingping
    Jiang, Kaida
    Li, Qingwei
    Zhang, Yanlei
    Cheng, Yan
    Lin, Ziyi
    Xuan, Jianwei
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (05) : 439 - 446
12345